Literature DB >> 10582684

Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.

S H Lee1, M S Shin, H S Kim, H K Lee, W S Park, S Y Kim, J H Lee, S Y Han, J Y Park, R R Oh, J J Jang, J Y Han, J Y Lee, N J Yoo.   

Abstract

Chromosome 8p21-22 is a frequent site of allelic deletions in many types of human tumors, including non-small cell lung cancer (NSCLC). Tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) is a cell-surface receptor involved in cell death signaling. The TRAIL-R2 gene recently has been mapped to chromosome 8p21-22. To explore the possibility that the TRAIL-R2 gene might be the relevant gene to the frequent deletion of 8p21-22 in NSCLC, we have analyzed the entire coding region and all splice sites of TRAIL-R2 for the detection of the somatic mutations in a series of 104 NSCLCs. Overall, 11 tumors (10.6%) were found to have TRAIL-R2 gene mutations in the death domain known to be involved in the transduction of an apoptotic signal. Our data indicate that somatic mutation of TRAIL-R2 may play a role in the pathogenesis of some NSCLCs and that the TRAIL-R2 gene is one of the genes relevant to the frequent loss of chromosome 8p21-22 in NSCLC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells.

Authors:  Y Oh; Y-J Jeon; G-S Hong; I Kim; H-N Woo; Y-K Jung
Journal:  Cell Death Differ       Date:  2012-01-13       Impact factor: 15.828

2.  The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.

Authors:  Yigang Wang; Fang Huang; Haibo Cai; Yumei Wu; Guoqing He; Wen-Song Tan
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-07       Impact factor: 4.553

3.  TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer.

Authors:  Matthew B Schabath; Anna R Giuliano; Zachary J Thompson; Ernest K Amankwah; Jhanelle E Gray; David A Fenstermacher; Kristen A Jonathan; Amer A Beg; Eric B Haura
Journal:  Carcinogenesis       Date:  2013-07-09       Impact factor: 4.944

Review 4.  The therapeutic potential of TRAIL receptor signalling in cancer cells.

Authors:  R Yerbes; C Palacios; A López-Rivas
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

Review 5.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

6.  O⁶-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas.

Authors:  Seung-Ho Yang; Keun Soo Lee; Hea Jung Yang; Byeong Hwan Jeon; Youn Soo Lee; Suk Woo Nam; Dong-Sup Chung; Sang Won Lee; Yong-Kil Hong
Journal:  J Neurooncol       Date:  2011-07-27       Impact factor: 4.130

Review 7.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

8.  Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY.

Authors:  Romone M Fancy; Lingyun Wang; Thomas Schmid; Qinghua Zeng; Hong Wang; Tong Zhou; Donald J Buchsbaum; Yuhua Song
Journal:  J Biol Chem       Date:  2016-04-22       Impact factor: 5.157

9.  Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study.

Authors:  Hongyi Yang; Yuhua Song
Journal:  J Mol Model       Date:  2016-03-19       Impact factor: 1.810

10.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Authors:  D Chitale; Y Gong; B S Taylor; S Broderick; C Brennan; R Somwar; B Golas; L Wang; N Motoi; J Szoke; J M Reinersman; J Major; C Sander; V E Seshan; M F Zakowski; V Rusch; W Pao; W Gerald; M Ladanyi
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.